Advertisement
Advertisement
Money /

Investment Products

Related Topics:
Stocks
Banking & finance
Hong Kong’s stablecoin initiative is part of efforts to become a global digital-asset hub. Photo: Getty Images
Banking & finance

Hong Kong’s anticipated stablecoin licence by end-March does not materialise

Analysts say the delay is most likely administrative and that the overall plan is still on track.

videocam
Banking & finance

Chinese company to use AI-powered testing to boost profits and fast-track IVF

videocam
Banking & finance

Insilico Medicine signs AI drug development deal with Eli Lilly

Banking & finance

Asian private equity values cash flow as fundraising falls to 12-year low

Advanced manufacturing and healthcare attract more attention at the expense of technology, media and telecommunications, Bain & Co says.

An employee works on a robot production line at Inovance Group in Jiangning District of Nanjing, in east China’s Jiangsu province, on March 17, 2026. Photo: Xinhua
An employee works on a robot production line at Inovance Group in Jiangning District of Nanjing, in east China’s Jiangsu province, on March 17, 2026. Photo: Xinhua
China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

Banking & finance

Hong Kong export credit insurer keeps premiums low despite Middle East tensions

Agency says limited exposure to the Middle East has kept trade risks contained for most Hong Kong exporters.

Advertisement
Advertisement
Advertisement
Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.

Staff members dispense medicines at a pharmacy in Wuhan, in central China’s Hubei province, on February 27, 2020. Photo: Xinhua
Staff members dispense medicines at a pharmacy in Wuhan, in central China’s Hubei province, on February 27, 2020. Photo: Xinhua
IPO

HSBC chairman floats ‘IPO connect’ for Hong Kong, Shenzhen listings

Modelled on Stock Connect, the proposal would give investors in the Greater Bay Area cross-border access to new share listings.

Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Hong Kong stock market

The big cornerstone comeback: what’s driving investors back to Hong Kong IPOs?

After four subdued years, the cornerstone investors that anchor Hong Kong’s IPO market are returning in force, reshaping the deal landscape.

Illustration: Lau Ka-kuen
Made in China 2025

Chinese healthcare firms expand overseas to support growing expat community

Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.

Distinct Healthcare raised HK$284.53 million from its initial public offering in Hong Kong last week. Photo: Handout
Distinct Healthcare raised HK$284.53 million from its initial public offering in Hong Kong last week. Photo: Handout
Banking & finance

Mainland China’s investors pour into Hong Kong-listed drug stocks

An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.

Made in China 2025

Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal

The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.

Banking & finance

Chinese gold, silver investors face gut check amid volatility, fund suspensions

Some retreat to the sidelines as another fund suspends new investments and futures plunge, while others remain determined to buy the dip.

A saleswoman adjusts gold jewellery for sale at a shop in Lianyungang, in China’s eastern Jiangsu province, on December 24, 2025. Photo: AFP
Hong Kong property

SHKP posts another Sierra Sea sell-out as Hong Kong property rebound strengthens

Fifth consecutive sell-out at Sai Sha development shows recovery gathering pace, with analysts forecasting further price increases ahead.

The latest Sierra Sea offering includes 244 two-bedroom and 106 three-bedroom units. Photo: Edmond So
The latest Sierra Sea offering includes 244 two-bedroom and 106 three-bedroom units. Photo: Edmond So
Banking & finance

The ‘biology winter’ thaws: why investors are buying Hong Kong’s biotech IPOs

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are surging.

Fintech

Digital finance in 2026: what to expect as pilots move into real-world adoption

While digital money experiments promise greater efficiency, they also risk deeper fragmentation and regulatory pitfalls, experts warn.

Advertisement
Advertisement
Advertisement
Made in China 2025

China’s rising biotech clout on show in flurry of billion-dollar licensing deals

A burst of overseas licensing pacts is spotlighting China’s biotech sector, as Jacobio, Coherent Biopharma and Harbour BioMed land deals.

The latest transactions reflect a broader pattern of multinational drugmakers turning to Chinese biotechs for pipeline replenishment. Photo: Shutterstock
The latest transactions reflect a broader pattern of multinational drugmakers turning to Chinese biotechs for pipeline replenishment. Photo: Shutterstock
Banking & finance

Gold takes centre stage as Hong Kong builds commodities ecosystem

Hong Kong plans to build an international gold trading centre as part of a wider commodities hub push.

Banking & finance

Hong Kong launches HKEX Tech 100 Index in pivot towards innovation-driven growth

Unveiling of benchmark tracking Hong Kong-listed tech firms comes amid a wave of property stock delistings.

Wealth management

China’s rich step up offshore bets as gold and insurance gain favour

China’s wealthy are shifting more of their portfolios offshore, as they seek to hedge slowing growth, policy risks and low yields at home.

As economic headwinds persist, China’s wealthy are becoming more cautious, using gold and insurance to preserve capital. Photo: XInhua
Banking & finance

China’s JD.com unit Jingdong Industrials aims for US$412 million Hong Kong IPO

Seven cornerstone investors led by London-based M&G Investments pledge a total of US$170 million.

JD.com will retain a 72 per cent stake after the listing. Photo: Reuters
JD.com will retain a 72 per cent stake after the listing. Photo: Reuters
Banking & finance

From chips to noodles: the newcomers testing Hong Kong’s buoyant IPO market

A wave of billion-dollar offerings is building behind four new listings this week, signalling sustained momentum in Hong Kong’s IPO market.

Banking & finance

Hong Kong taps Value Partners, 9 others to manage US$385 million residency fund

Government investment arm HKIC also names Primavera among managers of CIES IP, which focuses on Hong Kong’s long-term development.

Banking & finance

Hong Kong retail funds hit record pace, surpass 2024 full-year total

Gross sales reach US$82.6 billion in the first three quarters as investors pile into fixed-income funds: HKIFA.

There is renewed investor confidence in Hong Kong’s retail fund market, analysts say. Photo: Dickson Lee
Help preserve 120 years of quality journalism.
SUPPORT NOW